Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ...
Analysis and insights for driving a rapid transition to net-zero while building resilience to physical climate impacts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback